NORML

APRIL 30, 2020

According to state-registry records, “Chronic pain is currently and historically the most common qualifying condition reported by medical cannabis patients (67.5 ” This finding is hardly a surprise, as cannabis is well-established to mitigate pain in clinical models, particularly in patients with neuropathy.

Chronic Pain 337

Chronic Pain Clinical Trials Data Patients 337

NORML

MARCH 30, 2020

They reported “circumstantial evidence” suggesting that CBD may possess antiviral acticity in a limited number of conditions, specifically in the treatment of hepatitis C and Karposi sarcoma. Misleading claims represent both a threat to public health and a violation of consumer access to accurate information.”

CBD 292

CBD Clinical Trials Data Treatment 292

Cannabis Law Report

DECEMBER 14, 2021

IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The primary endpoint of our Phase 1 clinical trial was to test and demonstrate safety and tolerability.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma’s objective is to create and leverage a proprietary drug development platform in collaboration with an artificial intelligence and machine learning group to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

LifeCannMD

JULY 3, 2024

Various clinical trials are investigating the effectiveness of cannabis and its components in treating PTSD symptoms. Many patients report significant improvements in their PTSD symptoms with cannabis use and Florida has listed PTSD as a qualifying condition in order to obtain a Medical Marijuana card.

Treatment 96

Treatment Clinical Trials Marijuana Sleep 96

Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. References Staff, T.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. For more information, visit www.mymd.com. in the blood.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

NORML

JANUARY 31, 2019

Proposed federal legislation to direct the agency to conduct clinical trials on the use of cannabis for PTSD and for other conditions is currently pending in the US House and Senate. Additional information is available from the NORML fact-sheet, “Marijuana and Veterans Issues,” here.

Clinical Trials 195

Clinical Trials Chronic Pain Data Treatment 195

Veriheal

FEBRUARY 9, 2023

A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. This will offer professionals worldwide a chance to gain insight into this research, equipping them with valuable information they can apply in their own contexts.

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Veriheal

AUGUST 28, 2023

And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. Current approaches to treat this condition are helpful but do not always provide full relief. Do not attempt to self-diagnose or prescribe treatment based on the information provided.

Treatment 78

Treatment Clinical Trials Therapy Research and Development 78

MMJ Recs

JULY 30, 2024

Post-Traumatic Stress Disorder (PTSD) is a multifaceted mental health condition triggered by experiencing or witnessing traumatic events, persistently manifesting in symptoms like flashbacks, severe anxiety, and disrupted sleep. Need more information about medical marijuana as a treatment? Check it out today for additional information!

Therapy 116

Therapy Treatment Clinical Trials Sleep 116

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.” ” About PsyBio Therapeutics Corp.

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

MMJ Recs

JULY 9, 2024

Living with chronic conditions such as Multiple Sclerosis (MS) is profoundly challenging and impacts various aspects of daily life. of medical marijuana as a viable treatment option for certain conditions, including Multiple Sclerosis (MS), leading to increased advocacy for uniform regulations and broader accessibility.

Marijuana 111

Marijuana Treatment Cannabinoids Patients 111

Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. References Staff, T.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

CannaMD

JUNE 2, 2021

Of those states that had legalized medical marijuana, 14 currently consider Parkinson’s disease a qualifying condition for medical marijuana therapies. Of those who were provided information, the most common sources were non-Parkinson’s disease doctors, dispensary staff, and other individuals with Parkinson’s.

Patients 105

Patients Clinical Trials Treatment Research and Development 105

Veriheal

MAY 3, 2022

The outcomes and measures used throughout the trial included changes in CUD symptoms; anxiety and depressive symptoms; pain severity; and insomnia symptoms. Clinical Trial Sample Size. Missing Information. While lengthy, there is a surprising amount of missing information in the study.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

SEPTEMBER 9, 2021

MYMD-1 is also being developed as a potential therapy for COVID-19-related conditions such as post-COVID-19 syndromes. Supera-CBD is being developed to address anxiety, chronic pain, addiction, and seizures, and is on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. 646) 421-9523.

Pharmaceutical 97

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 97

Cannabis Law Report

AUGUST 17, 2021

Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. The condition is caused by inherited mutations in either the TSC1 gene or the TSC2 gene. Conference Call and Webcast Details.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

MMJ Recs

JULY 5, 2024

In states where it is legal, dispensaries report increasing sales of THC-infused products aimed at alleviating various health conditions. Understanding THC’s mechanisms and clinical implications is crucial as researchers continue to uncover its therapeutic potential and limitations in medical settings.

THC 52

THC Research and Development Chronic Pain Cannabinoids 52

Cannabis Law Report

JUNE 21, 2021

RYAH publishes monthly reports discussing various topics arising from their analysis of the reams of data in its proprietary RYAH Cloud database, offering a glimpse of how the information can be used. Most of the data came from five states that list these indications as qualifying conditions for the use of medical cannabis.

Data 105

Data Clinical Trials Research and Development Indica 105

MMJ Recs

JULY 11, 2024

It can be caused by a variety of factors, including medical conditions, psychological issues, or environmental factors. It can be caused by underlying health conditions, medications, or psychological factors. Comorbid Insomnia : Also known as secondary insomnia, it occurs alongside another medical or psychiatric condition.

Sleep 111

Sleep Treatment Research and Development Therapy 111

MMJ Recs

MAY 9, 2024

Many veterans struggle with various physical and psychological conditions resulting from their service. These professionals can provide valuable insights into whether medical cannabis is a suitable option based on the veteran’s medical history, current conditions, and treatment goals.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

JUNE 30, 2021

Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

MMJ Recs

JULY 3, 2024

From the pressures of work and personal relationships to the constant bombardment of information on social media and the news, many individuals find themselves struggling to cope with these challenges. The prevalence of anxiety disorders and stress-related conditions has risen significantly in recent decades.

CBD 52

CBD Research and Development Clinical Trials THC 52

Cannabis Law Report

MAY 10, 2022

More than half of all prescriptions for medicinal cannabis in Australia are written by doctors in Queensland, with prescriptions often given for conditions there is little evidence medicinal cannabis can treat, new research reveals. We are aware of clinical trials in that space, but not strong evidence.”.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

The Cannigma

MARCH 18, 2021

Taken together, the lack of guidance and lack of information about what treatments patients are taking, may underlie “inconsistencies in both use and reported effectiveness,” the researchers stated. Where do Parkinson’s patients get information about cannabis? Here are the most interesting statistics from the survey. Of the 43.9%

Patients 141

Patients Clinical Trials Treatment Cannabis 141

Medicinal Marijuana Association

FEBRUARY 11, 2024

You may have heard whispers of cannabis being used to address a specific eye condition, but what does the research truly reveal about its effectiveness? Glaucoma: Understanding the Condition Understanding glaucoma is crucial for recognizing its symptoms and seeking timely treatment.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

Cannabis Law Report

JANUARY 10, 2022

In addition, rising strategic initiatives by key players in the form of collaborations, clinical trials, and production are further contributing to increasing awareness and adoption of THCV products. Rising clinical trials is thus anticipated to boost the adoption and penetration of rare cannabis derivatives in the forthcoming years.

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. Excellent communication skills, especially in communicating regulations, contingencies, and technical information.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Canna Care Docs

OCTOBER 3, 2023

As a devastating diagnosis, patients with a terminal illness must not only learn to cope with this information about their health but find restorative ways to alleviate the most common symptoms and effects. This is largely due to the way THC interacts and binds with endocannabinoids in our ECS.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Cannabis Law Report

MAY 28, 2022

For more information, visit huschblackwell.com. We have been following the research and development of these medicines for psychiatric conditions such as PTSD and treatment-resistant depression. How did this come to fruition? We lateraled to Husch Blackwell together in April 2021 as part of a larger team.

Research and Development 52

Research and Development Therapy Clinical Trials Legalization 52

The Cannigma

MARCH 7, 2022

CBN’s ability to target CB2 receptors, in comparison to THC (which prefers the CB1 receptor), gives it better credibility in treating autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. What can the current clinical trials tell us?

THC 140

THC Sleep Clinical Trials Cannabinoids 140